Soleus Capital Management L.P. Purchases 17,400 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Soleus Capital Management L.P. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 29.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,800 shares of the biopharmaceutical company's stock after acquiring an additional 17,400 shares during the quarter. Alnylam Pharmaceuticals accounts for 1.1% of Soleus Capital Management L.P.'s holdings, making the stock its 27th largest holding. Soleus Capital Management L.P. owned 0.06% of Alnylam Pharmaceuticals worth $18,072,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Two Sigma Investments LP boosted its stake in Alnylam Pharmaceuticals by 459.4% in the fourth quarter. Two Sigma Investments LP now owns 107,117 shares of the biopharmaceutical company's stock valued at $25,206,000 after buying an additional 87,969 shares in the last quarter. Tema Etfs LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $3,841,000. Siemens Fonds Invest GmbH increased its position in Alnylam Pharmaceuticals by 137.7% during the 4th quarter. Siemens Fonds Invest GmbH now owns 3,245 shares of the biopharmaceutical company's stock worth $764,000 after purchasing an additional 1,880 shares in the last quarter. Silvercrest Asset Management Group LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $1,151,000. Finally, Quantinno Capital Management LP lifted its stake in Alnylam Pharmaceuticals by 35.4% in the 4th quarter. Quantinno Capital Management LP now owns 4,556 shares of the biopharmaceutical company's stock valued at $1,072,000 after purchasing an additional 1,190 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price for the company. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

Alnylam Pharmaceuticals Stock Down 1.2%

Alnylam Pharmaceuticals stock traded down $3.58 during midday trading on Thursday, reaching $289.00. The stock had a trading volume of 614,991 shares, compared to its average volume of 915,989. The company has a fifty day moving average price of $256.73 and a two-hundred day moving average price of $254.14. The company has a market capitalization of $37.68 billion, a P/E ratio of -133.18 and a beta of 0.17. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. The firm's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.16) EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.